anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The proposed clinical trial will be a Phase II, open label, single site study in subjects with somatostatin receptor positive tumours. Radioactive Lu-DOTA-TATE doses are fixed within a range of 1.85 - 5.55 GBq ± 10%, with individual doses based on specified risk factors. There will be two groups of subjects enrolled in this study. Group A subjects (primary therapy) will have progressive somatostatin receptor positive tumours and have never received Lu-DOTA-TATE. Group B subjects (maintenance therapy) will be those subjects who have previously received Lu-DOTA-TATE under the Special Access Programme (SAP) and will maintain their treatment schedule when they are entered into the study.

All subjects in Group A will be treated in an induction stage using 10-14 week dosing for up to 4 treatments. If an individual patient shows stable or improving disease status with no significant toxicities after the 4 induction treatments, they will be assessed 12-20 weeks after the last therapeutic treatment for entry into the maintenance stage. Patients will be re-assessed for stable or improving disease status with no significant toxicities 12-20 weeks after every other treatment of the maintenance stage for consideration of further maintenance treatments (re-evaluations), up to a maximum of 8 treatments per patient if there have been no significant toxicities or progression. At each treatment, an amino acid solution is infused prior to and during the Lu-DOTA-TATE infusion to protect the kidneys. Subjects will be followed for 6 months and 1 year (± 4 weeks) following their last treatment dose to determine progression-free survival, and for 2, 3, and 5 years (± 4 weeks) following their last treatment dose to determine overall survival. All subjects meeting evaluation criteria will be analysed for safety, and all Group A subjects who have received at least two treatments of Lu-DOTA-TATE will be evaluated for efficacy. Those Group B subjects with adequate baseline data for comparison collected retrospectively from a chart review study (REV-LUT-001) may also be evaluated for safety and efficacy. Additional optional characterization of tumour samples from subjects who have had surgery before or during the study may be performed to characterize NET tumour biology changes following Lu-DOTA-TATE treatment.
Participants with HD who have been treated with cyto-reductive chemotherapy, who are to undergo autologous stem cell transplantation, and who meet the inclusion/exclusion criteria are eligible to enter this study. The only changes to the standard of care is the addition of plerixafor to a G-CSF mobilization regimen on the day prior to apheresis and the collection of blood samples for pharmacokinetic (PK) analysis and pharmacodynamics (PD) analysis by CD34+ fluorescence-activated cell sorting (FACS) analysis. Blood samples for PK and CD34+ FACS analyses will be obtained prior to and after the first dose of plerixafor. Participants will undergo mobilization with G-CSF (10 µg/kg daily) and will receive plerixafor (240 µg/kg) on each day prior to apheresis. Participants will be apheresed for up to 5 consecutive days in order to collect the target number of CD34+ stem cells, (≥5\*10\^6 cells/kg). After apheresis, all participants will be treated with high dose chemotherapy in preparation for transplantation. Participants will be transplanted with cells obtained from the G-CSF plus plerixafor mobilization regimen. In the event that a sufficient number of cells for transplantation are not obtained from the collection, cells may be retained and pooled for transplantation at the investigator's discretion.

The primary endpoint is the proportion of HD participants who collect ≥5\*10\^6 CD34+ cells/kg with this mobilization regimen. The secondary endpoints include the safety of this mobilization regimen, the proportion of participants who collect ≥2\*10\^6 CD34+ cells/kg, the change in CD34+ cells circulating in the peripheral blood after a dose of plerixafor, and the number of days of apheresis required to obtain ≥5\*10\^6 CD34+ cells/kg. In addition, success of the transplantation will be evaluated by measuring the time to engraftment of PMNs and PLTs. Participants will be followed for 12 months to assess transplant durability.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.
1496751 Applying medicament to body canals XOMED INC 7 Jan 1976 [21 Aug 1975] 00530/76 Heading A5R Medicament is applied to the interior surfaces of a body canal e.g. an ear canal 12 by locating therein a radially compressed elongate body of dehydrated regenerated cellulose sponge and then hydrating the body so that it expands to fill the canal excepted for an axial opening 14. The body may be hydrated by body fluids or by a medicament containing liquid. The body may have an outer coating of a salve, ointment or cream and be packed prior to use in a moisture free environment. The compressed form of the body has a diameter from 30 - 80 percent less than its expanded form, e.g. a compression from 9mm diameter to 2mm.
The three-line anchor suture method is the same as before, the position is between the apex of the greater tubercle and the articular surface. After the rotator cuff is sutured, the bone bed beyond the suture point to the outer edge of the greater tubercle is opened with 2.0mm Kirschner wire every 5mm ( Crimson duvet), 1cm in depth, about 6 in total.
Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of \<100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.
Ponatinib tablets will be taken by mouth, continuously, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment can be taken with water, with or without food, at approximately the same time each day.
Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
Patients receive oral double placebo once daily. In both arms, treatment continues for 36 months in the absence of unacceptable toxicity or the development of an invasive malignancy.
Elderly patients, particularly those with reduced renal or hepatic function, may be at increased risk for developing erythromycin-induced hearing loss. (See ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION).

Elderly patients may be more susceptible to the development of torsades de pointes arrhythmias than younger patients. (See WARNINGS).

Elderly patients may experience increased effects of oral anticoagulant therapy while undergoing treatment with erythromycin. (See PRECAUTIONS - Drug Interactions).

Erythromycin ethylsuccinate for oral suspension 200 mg/5 mL contains 106.9 mg (4.6 mEq) of sodium per individual dose. 

Erythromycin ethylsuccinate for oral suspension 400 mg/5 mL contains 106.9 mg (4.6 mEq) of sodium per individual dose.

Based on the 200 mg/5 mL strength, at the usual recommended doses, adult patients would receive a total of 855.2 mg/day (37.2 mEq) of sodium. Based on the 400 mg/5 mL strength, at the usual recommended doses, adult patients would receive a total of 427.6 mg/day (18.6 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as congestive heart failure.
Doripenem is an antibiotic medication not yet approved by the US FDA. This is a phase 3, multi-center, prospective, open-label, single-arm study of doripenem in the treatment of complicated lower urinary tract infection or pyelonephritis in adults. Patients are hospitalized, but subsequently, patients may treated as outpatient or through home-based therapy at the discretion of the investigators. Conventional laboratory data will be collected from patients at specified times throughout the study. The primary endpoint is microbiological response measured at test of cure visit. The patients will receive doripenem with duration of therapy up to 10 days.
The INPP Movement Program Group will consist on a group of children aged between 7 and 9 years old enrolled in the second grade class of a catalan school that will participate in the school motor program provided by the Institute of Neuro-Physiology Psychology (INPP). This program consists of exercises that replicate the developmental movements of babies. Each day, a set of specific exercises will be performed, it will be practiced for 6 weeks and replaced by another set of exercises. They will be conducted for 15 minutes daily throughout the entire academic year.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic molding apparatus and method where a molding condition can precisely be set and a space is saved.  <P>SOLUTION: A Peltier element 22 which can be heated or cooled is arranged on the outer surface of a mold 10 which can be filled with lip stick material. A control part 24 controls a current value to energize the Peltier element 22 and the direction of current to control the temperature of the mold 10 through the Peltier element 22. Thus, the temperature of the mold 10 is controlled easily, and set precisely. Thus, a high-quality lip stick is molded. Moreover, a temperature history on which the crystal structure of the lip stick etc. depends is adjusted flexibly.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
BACKGROUND: The effect of analgesic modalities on short-term outcomes in acute pancreatitis remains unknown. However, preclinical models have raised safety concerns regarding opioid use in patients with acute pancreatitis.
OBJECTIVE: This study aimed to assess the association between analgesics, particularly opioids, and severity and mortality in hospitalised patients with acute pancreatitis.
METHODS: This prospective multicentre cohort study recruited consecutive patients admitted with a first episode of acute pancreatitis between April 1 and 30 June 2022, with a 1-month follow-up. Data on aetiology, clinical course, and analgesic treatment were collected. The primary outcome was the association between opioid analgesia and acute pancreatitis severity, which was analysed using univariate and multivariate analyses.
RESULTS: Among a total of 1768 patients, included from 118 centres across 27 countries, 1036 (59%) had opioids administered on admission day, and 167 (9%) received opioids after admission day. On univariate analysis, moderately severe or severe acute pancreatitis was associated with male sex, Asian ethnicity, alcohol aetiology, comorbidity, predicted severe acute pancreatitis, higher pain scores, longer pain duration and opioid treatment (all p < 0.001). On multivariate analysis, comorbidity, alcohol aetiology, longer pain duration and higher pain scores increased the risk of moderately severe or severe acute pancreatitis (all p < 0.001). Furthermore, opioids administered after admission day (but not on admission day) doubled the risk of moderately severe or severe disease (OR 2.07 (95% CI, 1.29-3.33); p = 0.003). Opioid treatment for 6 days or more was an independent risk factor for moderately severe or severe acute pancreatitis (OR 3.21 (95% CI, 2.16-4.79; p < 0.001). On univariate analysis, longer opioid duration was associated with mortality.
CONCLUSION: Opioid treatment increased the risk of more severe acute pancreatitis only when administered after admission day or for 6 days or more. Future randomised studies should re-evaluate whether opioids might be safe in acute pancreatitis.
* Testosterone gel is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate [ see Warnings and Precautions (5.1), Adverse Reactions (6.1), and Nonclinical Toxicology (13.1)]. 
  * Testosterone gel is contraindicated in women who are or may become pregnant, or who are breastfeeding. Testosterone gel may cause fetal harm when administered to a pregnant woman. Testosterone gel may cause serious adverse reactions in nursing infants. Exposure of a female fetus or nursing infant to androgens may result in varying degrees of virilization. Pregnant women or those who may become pregnant need to be aware of the potential for transfer of testosterone from men treated with testosterone gel. If a pregnant woman is exposed to testosterone gel, she should be apprised of the potential hazard to the fetus [ see Warnings and Precautions (5.2) and Use in Specific Populations (8.1, 8.3)].
The invention relates to a fusion protein for delivering hVEGI-192, a preparation method, a protein delivery system and application thereof, relates to the fields of genetic engineering and pharmaceutical preparations, and relates to the fields of genetic engineering and pharmaceutical preparations. The thermosensitive self-assembled nanoscale slow-release fusion protein delivery system comprises transferrin receptor targeting polypeptide, human vascular endothelial growth inhibitor VEGI-192 polypeptide and elastin-like polypeptide. The particle size of the fusion protein delivery system is about 20-40 nm. The invention has the function of targeting tumor vascular endothelial cells and triple negative breast cancer tumor cells. Can be made into solution or lyophilized preparation for administration by intraperitoneal injection or subcutaneous injection. The invention is a nano-scale temperature-sensitive delivery system capable of safely and effectively delivering hVEGI-192 to TNBC and tumor vascular sites in a targeted manner, has the functions of inhibiting TNBC growth and inhibiting blood-borne metastasis, and has the characteristics of simple preparation process, low cost, higher fusion protein yield, high product purity and the like.
A moulding composition comprises a polymerizable mixture of (i) a particulate copolymer comprising one or more C2-C4 alkanol esters of methacrylic acid and one or more C2-C12 alkanol esters of acrylic acid and (ii) a monomeric polymerizable fluid containing a mixture of C2-C18 alkanol esters of acrylic and/or methacrylic acid.  In addition to the above components the copolymer and/or the polymerizable fluid may comprise a cross-linking agent, e.g. an ester of acrylic and/or methacrylic acid with a polyhydric alcohol.  Also present may be a plasticizer, e.g. esters of acetyl citric, phthalic, sebacic and myristic acid, and a polymerization catalyst, e.g. benzoyl peroxide.  The compositions are polymerized to form dental protheses and artificial tissue material for the human body.  In the example a copolymer of isopropyl methacrylate, ethyl and amyl acrylates and diglycol dimethacrylate is formed into a paste with a mixture of butyl acrylate, ethyl and octyl methacrylates and glycol dimethacrylate.
An ingredient extraction method of facilitating blood sugar regulation and reducing blood lipids takes the root portion of pigeon pea (Cajanus cajan) from the plant of pigeon pea. More specifically, the root of the plant of pigeon pea is taken, and Cajanus cajan root (CCR) then is rinsed to further perform sterilization procedure for the surface of CCR within 95% of ethanol. Afterward it is rinsed within sterilized distilled water, and the CCR, in which its surface has been sterilized, is ground. The semi-finished product is added with 50-90% of alcohol having 10-20 times of volume. A portion of CCR powder in which its surface has been sterilized is extracted using 97 ± 2 DEG C hot water at 1:20 proportional weight in volume (w/v). After finishing, the powder is immersed at room temperature for 72 hours. Finally, the semi-finished product is filtered by a qualitative filter paper to obtain filtered liquid after completing. The filtered liquid is performed with freeze-drying after concentrating 10 times under reduced pressure. The extraction rate ranges for hot water cajan root (HWCR) of CCR and 95% ethanol extract (EECR) are respectively 6.7% and 5.0%.
INTRODUCTION: Medication holidays in inflammatory bowel disease (IBD) offer a potential means to balance disease management, costs, and quality of life. This concept is increasingly relevant in light of the chronic nature of IBD, the cumulative side effects associated with long-term pharmacotherapy, and the evolving treatment landscape that now includes a large armamentarium of effective induction, maintenance, and rescue therapies paired with disease monitoring tools that enable early intervention.
AREAS COVERED: This review critically examines the rationale, implementation, and risks of medication holidays in IBD. Recent evidence is reviewed to help guide the risks of relapse involved with cessation of therapy. The selection criteria for patients, the necessary monitoring protocols, and strategies for managing potential relapses are outlined.
EXPERT OPINION: Despite the potential benefits, medication holidays in IBD involve significant risks and require careful patient selection and active management. Current research highlights a need for improved predictive models and a deeper understanding of patient-specific outcomes and consequences. The future of medication holidays will depend heavily on advancements in noninvasive monitoring technologies and more personalized approaches to therapy. Ultimately, establishing clearer guidelines for safely conducting medication holidays will be crucial in integrating this strategy into routine clinical practice.
A microRNA (miRNA) inhibitor, being able to form a stable DNA-RNA double-stranded structure with a miRNA. The double-stranded structure comprises: (i) a miRNA unit sequence, and (ii) an RNA zipper unit sequence. The 5'-end of the RNA zipper unit sequence is connected to the 5'-end of the miRNA unit sequence. The 3'-end of the RNA zipper unit sequence is connected to the 3'-end of the miRNA unit sequence. The RNA zipper can connect the head of the miRNA molecule to the tail of the miRNA molecule to form a stable long-chain structure. The RNA zipper unit sequence contains 1-3 nucleotides not connected to the miRNA unit sequence. The DNA-RNA double-stranded structure can be used to inhibit biological activities of a miRNA unit, does not have biological toxicity, and has the advantages of high affinity, high specificity and high stability.
Disclosed in the present invention is a method for treating a polluted water body by using a water quality regulator. The water quality regulator comprises acidic calcium sulfate. Pollutants in polluted water bodies comprise blue-green algae, green algae, moss or spirogyra. The acidic calcium sulfate has great safety; and, at a use dilution ratio of 1/3000, an alga removing effect can be achieved just after half an hour, and blue-green algae obviously settle and die after one hour. The water quality regulator is remarkably better than several commonly-used chemical algaecides currently on the market. The water quality regulator causes no secondary pollution, is non-corrosive, has low cost, can be widely used, and is easy to use, thereby being very suitable for emergency treatment and control of blue-green alga outbreak.
1. The use of a compound selected from: (a) an SK-3 calcium activated potassium channel polypeptide; (b) a compound which acitvates an SK-3 calcium activated potassium channel polypeptide; (c) a compound which inhibits an SK-3 calcium activated potassium channel polypeptide; or (d) a polynucleotide encoding an SK-3 calcium activated potassium channel polypeptide; for the manufacture of a medicament for treating: (i) dysfunctions of male or female sexual organs; or (ii) vascular disorders such as angina, stroke and hypertension. 2. The use according to claim 1 wherein the medicament is used in the treatment of sexual dysfunction and vascular disorders. 3. The use according to claim 1 wherein the medicament comprises a compound which specifically activates or inhibits an SK-3 calcium activated potassium channel polypeptide. 4. A method of screening for compounds that act as agonists or antagonists of SK-3 calcium activated potassium channel polypeptides for use in the preparation of a medicament for treating dysfunctions of male or female sexual organs or vascular disorders such as angina, stroke and hypertension.
PURPOSE: To obtain a cosmetic composition having unique appearance and moisturizing effect by incorporating a transparent gel base with a mixture comprising at least two kinds of cholesteryl ester liquid crystal and pearl and/or pigment in a heterogeneous state. CONSTITUTION: This cosmetic composition is obtained by incorporating a transparent gel base of transparent gel-type cosmetic with a liquid crystal mixture comprising at least two kinds of cholesteryl ester and pearl (e.g. mica/titanium dioxide, mica/titanium dioxide/iron oxide, guanine pearl) and/or pigment (e.g. iron oxide, chromium hydroxide, titanium dioxide) in a heterogeneous state (e.g. linearly, granularly). In this case, the liquid crystals are selected from the group consisting of cholesteryl acetate, cholesteryl isosteryl carbonate, cholesteryl chloride, cholesteryl capronate and the like. This cosmetic composition presents hue change as temperature changes.
The object of the present invention is an anti-age composition comprising a combination of antioxidant agents in association with Bifidobacteria and cell walls isolated from probiotics which takes into account all the different factors involved in the aging process in order to prevent or slow down the course thereof. Cell homeostasis is under the control of redox systems. An unbalance of this control leads to the release of ROS (Reactive Oxygen Species) and RNS (Reactive Nitrogen Species) causing severe damages to cells, thereby triggering the aging process. Under physiological conditions antioxidant substances are naturally produced, such as, for example, the superoxide dismutase, being able to counteract the detrimental action of ROS and RNS to the cells. In order to fight the detrimental effects of ROS and RNS, which are the key players in the aging process, substances, such as flavonoids, anthocyanins, tannins, curcumin and derivatives thereof, as well as vitamins A, C and E were found to be able to inactivate free radicals and, subsequently, the detrimental effects thereof. Moreover, it has been fully demonstrated that homeostasis of intestinal flora is fundamental for individual's well-being. In particular, the persistence of a high amount of Bifidobacteria, as major agents of the beneficial action on the intestinal flora is well proved. On the other hand, it is well known that a strong relationship between metabolism and immune system exists.
Infants randomised to receive vaccines at home visits shortly after birth will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine (BCG-Denmark 1331 (Statens Serum Institute) or BCG Japan (Japan BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination. For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth.
Devices and systems used to inspect and evaluate components. Some embodiments include an imaging system, positioning system, and controller. A robotic manipulation can be provided to manipulate the component. Some embodiments include an illumination system. A graphical user interface can be used to develop and/or run inspection protocols. A fuzzy logic analysis can be coupled with one or more devices/systems to provide evaluation of an inspection.